Three Chart Setups Emerge as SanDisk, Coinbase, and Moderna Consolidate After Big Moves

Key Takeaways

• SanDisk (SNDK) is reportedly sold out of memory and NAND flash production through 2026, with analyst estimates projecting continued growth into 2027.
• Coinbase (COIN) shares recaptured their 200-day moving average on volume running 150% above the 50-day average after the SEC approved limited on-chain trading of tokenized stocks.
• Moderna (MRNA) surged 176% in a single session in mid-August after Phase 3 data showed its mRNA cancer therapy meaningfully reduced melanoma recurrence rates.
• The source methodology targets fundamentally sound stocks in uptrends that have consolidated for five weeks or longer before a potential resumption.

SanDisk, Coinbase, and Moderna have each formed technical consolidation patterns following sharp advances, drawing attention from chart-focused analysts. Each stock carries a distinct catalyst—AI memory demand, crypto regulatory developments, and a cancer therapy breakthrough—that preceded the base formations.

Numbers at a Glance

Moderna Single-Day Surge

176%

MRNA's move on mid-August Phase 3 data; the stock has since traded sideways on low volume.

Coinbase Volume Spike

150% above 50-day norm

Friday volume level when COIN recaptured its 200-day moving average after SEC news.

SanDisk's Sold-Out Position and AI Storage Demand

SanDisk (SNDK) has emerged as one of the stronger performers during the current AI investment cycle, according to the source. The company supplies high-capacity flash storage products used in cloud infrastructure and AI deployments, and it has reportedly exhausted its memory and NAND flash production capacity through the end of 2026. Analyst consensus estimates tracked by Zacks project that growth momentum will extend into 2027.

Following a substantial price advance, the stock formed a multi-month base and is currently described as being in a monthly bull flag pattern. The setup reflects the broader methodology outlined in the article: waiting for a consolidation of five weeks or more within an uptrend before considering an entry, rather than pursuing shares already extended from a prior breakout.

Regulatory Shifts Shape Coinbase's Technical Recovery

Coinbase (COIN) experienced a pullback earlier this month when the "CLARITY Act," a piece of cryptocurrency legislation, stalled in the U.S. Senate. The setback was short-lived. Shares rebounded sharply on Friday after the SEC independently approved limited on-chain trading of tokenized stocks, a decision that bypassed the legislative impasse. Volume on that session reached 150% above the 50-day average, and the stock closed back above its 200-day moving average—a level technically significant to trend-following investors.

The source also notes that Coinbase is reportedly engaged in discussions with the Treasury and Commerce Departments around the Strategic Bitcoin Reserve, adding a separate potential catalyst to its near-term picture. The combination of a volume-backed technical recovery and policy-level engagement represents the type of renewed demand signal the article's screening methodology looks for.

Moderna's situation differs in its origin but shares the same structural characteristic. The company's Phase 3 trial data, released in mid-August, showed its mRNA-based cancer therapy significantly reduced melanoma recurrence. Given that more than 2% of Americans have melanoma, the source describes the addressable market as large enough to support blockbuster commercial potential. Since the 176% single-day jump, MRNA has moved sideways on declining volume—behavior the article interprets as holders being unwilling to sell, forming what is characterized as a high-tight flag pattern.

InvestorStack Lens

The three setups share a common structure: a sharp catalyst-driven advance followed by a low-volume consolidation. For technically oriented investors, the Coinbase volume data—150% above its 50-day norm on a moving-average recapture—is the most concrete, measurable signal in the group. Whether that volume reflects durable institutional interest or a short-covering spike is not determinable from the source alone, and investors should weigh that uncertainty before drawing conclusions about trend durability.

What Could Challenge This View

The strongest pushback against a broadly bullish reading is that each catalyst carries unresolved risk. SanDisk's sold-out status could reflect a temporary demand surge rather than structural growth. Coinbase's recovery rests on an SEC administrative action that could face legal challenges or reversal, and the CLARITY Act remains stalled. Moderna's therapy has not yet reached commercial launch, meaning revenue realization is still prospective. A consolidation pattern alone does not neutralize fundamental uncertainty in any of these cases.

What to Watch Next

• Whether the CLARITY Act advances or remains stalled in the U.S. Senate, which directly affects Coinbase's regulatory environment.
• Any update on Coinbase's reported discussions with Treasury and Commerce Departments regarding the Strategic Bitcoin Reserve.
• Moderna's path toward commercialization of its mRNA melanoma therapy following Phase 3 data.
• Whether SanDisk provides guidance on production capacity beyond 2026 and whether analyst estimates for 2027 hold or get revised.
• Volume behavior in all three stocks during subsequent weeks—the methodology specifically watches for high-volume breakouts from these base structures.